Impact Factor
4.22
Journal Citation Impact
Estimated influence, citation density, publishing volume, and citation integrity from the analytics table.
Citation rate
4.16
7,738 total citations
h5-index
90
h5 depth signal
Cited share
80.5%
1,629 of 2,024
Total citations
7,738
Citation footprint
Metric signal
3.50
External metric anchor
Self-citation
8.7%
677 self-citations
Citations Trend
Monthly Publications Cadence
Citing Geographic Demographics
United States
4,846
United Kingdom
1,385
China
1,192
Australia
898
Canada
826
Citing Fields of Research
Virology
4,500
Immunology
2,243
Healthcare Policy
1,788
Health Education & Remote Healthcare
1,507
Antibiotic & Antibacterial Agents
1,290
Publishing Activity & Reach
Volume, recency, access pattern, and citing-community signals from the journal analytics record.
All-time article footprint
33,106
Articles tracked across the journal lifetime
Indexed publication set
2,024
1,629 cited publications
Last 12 months
1,171
97.6 publications/month
Open access share
51.8%
606 OA publications in the last year
Leading citing country
United States
4,846 citing publications
Leading citing field
Virology
4,500 citing publications
Latest tracked publication
20 October 2026
10 recent records available
Coverage & Indexing History
v1n1, 1983-
v1n1, 1983-
Active Coverage
Research Focus & Classification
Indexed Subjects
Virology
Immunology
Health Education & Remote Healthcare
Oncology
Healthcare Policy
Antibiotic & Antibacterial Agents
Broad Categories
Allergy and Immunology
Virology
MeSH Descriptors
Vaccines
Latest Publications
Recent article records with DOI-first linking and condensed abstracts.
01
DOI 10.1016/j.vaccine.2026.129265
Open DOI
Quantifying the impact of pathogen interactions on vaccine effectiveness estimates in the test-negative design
02
DOI 10.1016/j.vaccine.2026.129244
Open DOI
Cross-protection and type-replacement over the 17 years after human papillomavirus vaccine introduction in young women
03
04
DOI 10.1016/j.vaccine.2026.129237
Open DOI
AEX-1: A Vero cell variant with enhanced permissiveness for influenza virus replication
05
DOI 10.1016/j.vaccine.2026.129267
Open DOI
When models diverge: Harmonizing pneumococcal vaccination cost-effectiveness analyses to inform PCV20 and PCV21 use in US adults
06
DOI 10.1016/j.vaccine.2026.129238
Open DOI
What is actually the emerging evidence about non-specific vaccine effects in randomized trials from the Bandim Health Project?
07
08
DOI 10.1016/j.vaccine.2026.129171
Open DOI
Cost-effectiveness of universal infant hepatitis B vaccination programme in Finland
09
DOI 10.1016/j.vaccine.2026.129245
Open DOI
Corrigendum to “The case for model-informed vaccine development” [Vaccine 92 (2026) 128780]
10
Bibliographical & Catalog Notes
Vol. 13, no. 7 and v. 13, no. 14 (1995) have title: Vaccine. Adjuvant research.
Title from cover.
Imprint varies.
Also available online.
Vol. 4, no. 1 (1986)19900917 Notice not published Printed on acid-free paper